BioSpace News Archive

Insulet Corporation announced FDA 510(k) clearance of the Omnipod DASHTM Insulin Management System (Omnipod DASH).

RDD Pharma announced the appointment of Dr. Mark Sirgo as the Chairman of the Board of Directors.

Gryphon Investors announced that it has made a majority investment in Water’s Edge Dermatology.

Blueprint Medicines Corporation and CStone Pharmaceuticals announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan.

Care coordinators across Michigan are converging for the 2018 Connecting Michigan for Health Conference, 4medica will be on hand to address one of the most dangerous errors taking place in healthcare today: patient mismatching.

Ichor Medical Systems, Inc. (Ichor) announced today the first in human dosing of JNJ-64300535 with its next generation investigational TriGrid® Delivery System.

Verastem, Inc. announced the grant of stock options to fourteen new employees to purchase an aggregate of 405,000 shares of Verastem Oncology’s common stock.

Bristol-Myers Squibb Company announced results from a part of the Phase 3 CheckMate -227 trial that evaluated Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) and Opdivo plus chemotherapy versus chemotherapy in patients with first-line advanced non-small cell lung cancer (NSCLC) with PD-L1 expression <1%, across squamous and non-squamous tumor histologies (Part 1b).

Antibe Therapeutics Inc. will be attending the 2018 BIO International Convention.

Synlogic, Inc. announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive Disease Week (DDW 2018)